Navigation Links
APIC Conference to Focus on Patient Safety and 'Targeting Zero' Initiatives to Reduce HAIs
Date:5/9/2008

he more than 75 topics on the week's agenda include:

-- "Treatment of MRSA Infections and Role for Decolonization,"

Chip Chambers, MD, Chief, Division of Infectious Diseases, University of

California, San Francisco, CA

-- "MDR/XDR Tuberculosis," Robert Belknap, Denver Public Health

Department, Denver, CO

-- "Surgical Center Hepatitis C Outbreak: Use of Unsafe Injection

Practices," Brian Labus, MPH, Senior Epidemiologist, Southern

Nevada Health District, Las Vegas, NV

-- "CMS's Value-Based Purchasing Activities," Mark A.

Levine, MD, Chief Medical Officer, Denver Region, Centers for Medicare

and Medicaid Services

-- "The Changing Epidemiology of Clostridium difficile," L.

Clifford McDonald, MD, Medical Epidemiologist, Centers for Disease

Control and Prevention (CDC)

-- "Collaboration with Public Health Partners - The Fight Against

MRSA," Bonnie M. Barnard, MPH, CIC, Surveillance Epidemiologist,

Montana Department of Public Health and Human Services, Helena, MT

"We are pleased to host such an esteemed group of experts at this year's Annual Conference," said APIC's 2008 President Janet E. Frain, RN, CIC, CPHQ, CPHRM, Director, Integrated Services, Sutter Medical Center in Sacramento, CA. "Our members will benefit from this learning experience and be better positioned to lead performance improvement initiatives that will reduce the risk of HAIs and save lives."

Please visit http://www.apic.org for further information.

APIC's mission is to improve health and patient safety by reducing risks of infection and other adverse outcomes. The Association's nearly 12,000 members have primary responsibility for infection prevention, control and hospital epidemiology in healthcare settings around the globe. APIC advances its mission through educatio
'/>"/>

SOURCE Association for Professionals in Infection Control andEpidemiology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
4. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2008)... 9 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: AD...lty pharmaceutical company,with operations in Chin...ceutical Inc., today announced that its consolidat...r 31, 2007, which were included in its,Annual Repo...ange,Commission on April 14, 2008, contained a ,go...
(Date:5/9/2008)... grain may provide protection against heart diseas...RLINGTON, Va., May 8 /PRNewswire/ -- Brown rice, a...d ranks of healthful whole grains, according,to an...g Administration,(FDA) that will allow brown rice ...This will enable consumers to easily identify brow...
(Date:5/9/2008)...f., May 9 /PRNewswire-USNewsire/ -- U.S.,corporati...elp victims of,the Cyclone Nargis in Myanmar are r... International, to ensure that the aid will reach ...It,s important to remember the complete story of t...with the people and organizations that,provide the...
(Date:5/9/2008)...RNewswire/ -- Summary: With the recent devastating...eaths and leaving over a,million people homeless, ...preneurs Sharon Tucci and Steve Jones have launche...ard awareness for humanitarian needs,with hopes o... initial goal,of having 1,000 individuals and comp...
Breaking Medicine News(10 mins):Health News:AMDL Reports Going Concern Qualification 2Health News:FDA Approves Health Claim for Brown Rice 2Health News:FDA Approves Health Claim for Brown Rice 3Health News:FDA Approves Health Claim for Brown Rice 4Health News:FDA Approves Health Claim for Brown Rice 5Health News:Direct Relief's Corporate Partners Key to Aiding Cyclone Victims 2Health News:New Web Site to Raise Awareness for the Myanmar Crisis Has Lofty Goals 2
...on an earlier discovery that a gene called IRF6 is... palate, researchers at the University of Iowa Roy...d their colleagues have identified the function of...e Oct. 15 in Nature Genetics, reveal an unexpected...
... of home care for several thousands of elderly peo...ectors.// According to the Commission for Social ...re givers too rushed, giving insufficient time to ...giving 15 minute slots of help, before moving on t...
...t government-sponsored reports released on Tuesday... in spite of the risks due to contamination. These.... "Overall, for major health outcomes among adult... outweigh the risks. Somehow, this evidence has be...
...accine has proved to be efficient on animals accor...ntario.// "Perhaps we can cure HIV infection. Th...sity of Western Ontario. Clinical trials of the va...i million to be invested by Curocom Co., a compan...
Other Medicine News:Health News:Gene Involved In Common Birth Defect Also Regulates Skin Biology 2Health News:Gene Involved In Common Birth Defect Also Regulates Skin Biology 3Health News:Standards of Home Care for Elderly Needs Change 2Health News:Eating Fish has more Benefits than Risks 2
(Date:5/8/2008)...Call/ -- DATATRAK International, Inc.,(Nasdaq: DA... global,eClinical solutions for the clinical trial...or the first quarter of 2008., For the three mont...mately 41% to $2,088,000 and the Company reported ...n both a basic and diluted basis. These,results co...
(Date:5/8/2008)...tial of asenapine in the treatment of ...GTON, May 8 /- Schering-Plo... an overview of asenapine clinical trials,from the... Meeting of the,American Psychiatric Association i..., involving patients with bipolar I disorder and s...
(Date:5/8/2008)...e-FirstCall/ -- VION PHARMACEUTICALS,INC. (Nasdaq...ator-sponsored,Phase I/II clinical trial of its le...combination with cytarabine in elderly patients wi... (AML) and high-risk,myelodysplastic syndromes (MD...on of Ellen K. Ritchie, M.D. at The Weill-Cornell ...
(Date:5/8/2008)...e-FirstCall/ -- AstraZeneca (NYSE:,AZN) today anno...plication,(sNDA) to the U.S. Food and Drug Adminis...rate) Extended-Release Tablets to seek approval fo...AD), including maintenance of,antianxiety effect. ...an,atypical antipsychotic medicine in GAD. The sub...
Breaking Medicine Technology:DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 1Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 2Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 3Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 4More Black Children Dying From Diabetes 6447 1More Black Children Dying From Diabetes 6447 2More Black Children Dying From Diabetes 6447 3Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 1Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 2Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 3TriWest Executive Advisory Board Marks Its Fifth Year 6438 1TriWest Executive Advisory Board Marks Its Fifth Year 6438 2TriWest Executive Advisory Board Marks Its Fifth Year 6438 3
...O, Calif., May 02, 2007 /PRNewswire/ -- Ceregene, ...Phase 1 trial of,CERE-110, a gene therapy product ...the treatment of Alzheimer,s disease. After one,ye...who received,CERE-110 in the trial indicate that a...erated, and an interim analysis suggested that,the...
....C.--(BUSINESS WIRE)--May 4, 2007 - Argos Therapeu...he immunosuppressive,properties of soluble CD83 at...eld in San Francisco, May 5-9. The presentations,w...e University of,Western Ontario., "These data sugg...ival in transplantation, and that it can also act,...
Other Medicine Technology:Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 2Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 3Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 4Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: